Abbott India witnesses incremental revenue in Q1FY17

Abbott India has declared its Q1FY17 results on Friday. The company’s revenue has increased by 15.83 per cent to Rs 738 crore in Q1FY17 as compared to same period in previous fiscal. Its EBITDA too has risen by 26.27 per cent to Rs 119 crore in Q1FY17 on a yearly basis. Abbott India’s EBITDA margin has expanded by 134 basis points to 16.17 per cent in Q1FY17 as compared to same period in previous financial year. The company’s net profit also has increased by 10.36 per cent to Rs 74 crore in Q1FY17 on a yearly basis. Its net profit margin has contracted by 53 basis points to 10.03 per cent in Q1FY17 as compared to same period in previous financial year.

The share price of Abbott India has increased by 2.5 per cent on bourses in early trades; and is trading at Rs 4720 on an intraday basis.

Abbott India’s business is divided into four categories viz. Women's Health, Gastroenterology and Hepatic Care; Specialty Care; General Care and Consumer Care. The company's brands include Digene, Duvadilan, Betonin Ast, Epilex, Heptral, Prothiaden, Brufen, Creon, Cremaffin Plus, Vertin, Thyronorm, Zolfresh, Udiliv and Duphalac.